Please login to the form below
insulin glargine
This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Latest news
-
Dupixent bounce-back helps stem diabetes declines at Sanofi
Overall sales at the French pharma group fell almost 6% to 8.3bn ($bn), pegged back by unfavourable exchange rates but also a further 21% drop for Lantus (insulin glargine) due
-
Sanofi poaches Peugeot's finance head
The group saw sales from its diabetes blockbuster Lantus (insulin glargine) plummet 18% to 911m (1.1bn) in the first quarter, quite a difference from the drug’s peak in 2014,
-
FDA starts review of Sanofi’s oral type 1 diabetes drug
Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine
-
Sanofi’s latecomer PD-1 gets date for FDA verdict
blockbuster Lantus (insulin glargine) and a poor start for dengue vaccine Dengvaxia.
-
Sanofi warns of difficult few months as diabetes sales slump
As in earlier quarters, the main damage has come from diabetes blockbuster Lantus (insulin glargine), which saw sales decline 18% to 911m ($1.1bn) in the first quarter having reached a
More from news
Approximately 23 fully matching, plus 110 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
agreement for the development and commercialisation of a follow‐ on insulin glargine product to Sanofi’s Lantus.
-
Mylan sees the UK paving the way for an insulin game changer
As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
-
Going the distance
In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
-
Pharma deals during February 2013
Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Sanofi promotes diabetes expert Paul Chew to chief medical officer
position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Global Antidiabetics Market is anticipated to grow at a CAGR of 10.6% by 2024
It offers huge opportunities industry players. Long-acting insulin provide basal insulin coverage. ... Long acting insulin analog includes insulin glargine (Lantus) and insulin detemir (Levemir) which will drive industry growth.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
New Business Director - PR
-
Competitive Salary and benefits
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical/ Scientific Director
-
Salary TBC
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Senior Medical Writer
-
Great salary and benefits
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Director, Market Access / HEOR - North-West
-
Negotiable
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Competitive Salary
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
Subscribe to our email news alerts
- The power of behaviour change lies in the basics
- Spectral Computed Tomography (CT) Market Global Briefing and Future Outlook 2018 to 2023
- Wearable Heart Monitoring Device Market to Witness Robust Expansion Throughout the Forecast Period 2018 to 2023
- Snoring Control Device Market Global Briefing and Future Outlook 2018 to 2023
- Smart Wellness Market Global Research Analysis 2018 to 2023
- Zinc Lactate Market Overview, Growth Forecast, Demand and Development Research Report to 2023
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
